http://pharmaweblog.com/blog/2007/03/27/alexion-sets-the-price-of-living-well-with-pnh-at-roughly-400k-a-year/ Pharmaceutical and biotech science and business Thu, 28 Aug 2008 19:57:18 +0000 http://wordpress.org/?v=2.0.2 http://pharmaweblog.com/blog/2007/03/27/alexion-sets-the-price-of-living-well-with-pnh-at-roughly-400k-a-year/#comment-107 Tue, 11 Dec 2007 16:45:51 +0000 http://pharmaweblog.com/blog/2007/03/27/alexion-sets-the-price-of-living-well-with-pnh-at-roughly-400k-a-year/#comment-107 [...] 3.  Eculizumab (Soliris, Alexion).  Eculizumab is a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation.  It is the first complement activation inhibitor approved for human use and is also the first drug indicated for Paroxsymal Nocturnal Hemoglobinuria (PNH), a rare, complement-mediated disease characterized by red blood cell destruction.  Eculizumab was approved for its ability to stabilize hemoglobin (49% versus 0% with placebo) and reduce transfusion requirements (mean 3 U versus 11 U with placebo) in PNH.  Eculizumab represents a tremendous clinical advance for PNH and represents clinical proof-of-concept for inhibition of complement activation generally.  Its downside is its exorbitant cost of nearly $400k per year, which keeps this innovation out of my top 3. [...] […] 3.  Eculizumab (Soliris, Alexion).  Eculizumab is a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation.  It is the first complement activation inhibitor approved for human use and is also the first drug indicated for Paroxsymal Nocturnal Hemoglobinuria (PNH), a rare, complement-mediated disease characterized by red blood cell destruction.  Eculizumab was approved for its ability to stabilize hemoglobin (49% versus 0% with placebo) and reduce transfusion requirements (mean 3 U versus 11 U with placebo) in PNH.  Eculizumab represents a tremendous clinical advance for PNH and represents clinical proof-of-concept for inhibition of complement activation generally.  Its downside is its exorbitant cost of nearly $400k per year, which keeps this innovation out of my top 3. […]

]]>